NEWS
World's First! AIM's Serum-Free Rabies Vaccine Heads for Market, Triple Technology Upgrade Leads Billion-Dollar Market
Recently, AIM Vaccines announced two major updates on its rabies vaccine development: its serum-free rabies vaccine completed Phase III trials, obtained production licenses, and will be submitted for marketing registration; its high-potency human diploid rabies vaccine received approval to start clinical trials. Truly, there is a series of good news.
As China's only fully integrated vaccine group covering the entire industry chain, AIM owns five technology platforms, four licensed production enterprises and seven R&D teams. As the world's second-largest rabies vaccine supplier, its commercialized freeze-dried Vero cell rabies vaccine has achieved a 100% batch release compliance rate for 16 consecutive years, covering over 2,000 disease control centers across 31 provinces and cities nationwide. In the first half of 2024, the product was awarded bids in international markets such as Pakistan and Egypt, accelerating its internationalization process.
In the area of rabies vaccines, AIM has established a rabies vaccine portfolio covering mainstream technological approaches, with three main products under development, as follows:
1. World's First Serum-Free Rabies Vaccine Nears Launch
Another rabies vaccine from AIM, a high-potency human diploid vaccine developed through an iterative process, has recently been approved for clinical trials by the National Medical Products Administration. Animal trials demonstrated that its antibody titers are significantly higher than those of existing similar products, and it overcomes the technical bottleneck of low virus titers in traditional processes. It also supports flexible vaccination methods such as the “five-dose schedule” and “four-dose schedule”. Human diploid vaccines, recognized by the WHO as the gold standard due to their high safety, are currently expensive and have limited production capacity. AIM has the potential to change this situation through process optimization and further consolidate its competitiveness in the high-end rabies vaccine market.
3. mRNA Rabies Vaccine Shows Disruptive Potential
Preclinical studies have shown that AIM's independently developed mRNA rabies vaccine, LVRNA001, requires only two doses to achieve a 100% protection rate, with antibody levels showing better durability than traditional inactivated vaccines. In post-exposure prophylaxis, its ability to rapidly induce antibodies (with a 100% seroconversion rate five days after initial immunization) effectively blocks viral invasion of the central nervous system, offering a better solution for high-risk exposed populations. Currently, no mRNA rabies vaccine has been marketed globally. AIM, alongside international companies like CureVac, is at the forefront of development and may reshape industry standards in the future.
In summary, AIM Vaccine has consolidated its global leadership in rabies vaccines through breakthroughs in three technological approaches: serum-free, high-potency human diploid, and mRNA. This also promotes the industry's shift from "reactive prevention" to "efficient and safe" solutions. As the three upgraded vaccines hit the market one after another, AIM will create a product matrix covering different price ranges and application scenarios, achieving dual growth of "technological premium" and "economies of scale" in both domestic and international markets. In the future, the scalability of its mRNA platform (e.g., RSV and shingles vaccine development) is expected to further expand its growth potential and lead China's vaccine industry into a new cycle of innovation-driven development.
As China's only fully integrated vaccine group covering the entire industry chain, AIM owns five technology platforms, four licensed production enterprises and seven R&D teams. As the world's second-largest rabies vaccine supplier, its commercialized freeze-dried Vero cell rabies vaccine has achieved a 100% batch release compliance rate for 16 consecutive years, covering over 2,000 disease control centers across 31 provinces and cities nationwide. In the first half of 2024, the product was awarded bids in international markets such as Pakistan and Egypt, accelerating its internationalization process.
In the area of rabies vaccines, AIM has established a rabies vaccine portfolio covering mainstream technological approaches, with three main products under development, as follows:
1. World's First Serum-Free Rabies Vaccine Nears Launch
AIM Vaccine's wholly-owned subsidiary has completed Phase III clinical trials of its serum-free iterative rabies vaccine. Results show that the vaccine meets all standards for safety, immunogenicity, and persistence. It has obtained a drug production license and will soon submit a marketing registration application. By completely removing animal serum components, the vaccine significantly reduces the risk of adverse reactions such as allergies, making it the world's first serum-free rabies vaccine to enter the final stage of commercialization. China as the world's largest rabies vaccine market (projected to reach a scale of RMB 14.8 billion by 2030), combined with the latest national policy requiring vaccination institutions to stock at least two types of vaccines, positions this product as a strong contender for becoming the preferred choice due to its technological advantages.
Another rabies vaccine from AIM, a high-potency human diploid vaccine developed through an iterative process, has recently been approved for clinical trials by the National Medical Products Administration. Animal trials demonstrated that its antibody titers are significantly higher than those of existing similar products, and it overcomes the technical bottleneck of low virus titers in traditional processes. It also supports flexible vaccination methods such as the “five-dose schedule” and “four-dose schedule”. Human diploid vaccines, recognized by the WHO as the gold standard due to their high safety, are currently expensive and have limited production capacity. AIM has the potential to change this situation through process optimization and further consolidate its competitiveness in the high-end rabies vaccine market.
3. mRNA Rabies Vaccine Shows Disruptive Potential
Preclinical studies have shown that AIM's independently developed mRNA rabies vaccine, LVRNA001, requires only two doses to achieve a 100% protection rate, with antibody levels showing better durability than traditional inactivated vaccines. In post-exposure prophylaxis, its ability to rapidly induce antibodies (with a 100% seroconversion rate five days after initial immunization) effectively blocks viral invasion of the central nervous system, offering a better solution for high-risk exposed populations. Currently, no mRNA rabies vaccine has been marketed globally. AIM, alongside international companies like CureVac, is at the forefront of development and may reshape industry standards in the future.
In summary, AIM Vaccine has consolidated its global leadership in rabies vaccines through breakthroughs in three technological approaches: serum-free, high-potency human diploid, and mRNA. This also promotes the industry's shift from "reactive prevention" to "efficient and safe" solutions. As the three upgraded vaccines hit the market one after another, AIM will create a product matrix covering different price ranges and application scenarios, achieving dual growth of "technological premium" and "economies of scale" in both domestic and international markets. In the future, the scalability of its mRNA platform (e.g., RSV and shingles vaccine development) is expected to further expand its growth potential and lead China's vaccine industry into a new cycle of innovation-driven development.
